文献速递慢阻肺肺结节与肺癌

电子鼻呼气分析前瞻性检测慢阻肺患者早期肺癌

Prospective Detection of Early Lung Cancer in Patients With COPD in Regular Care by Electronic Nose Analysis of Exhaled Breath.
PubMed 文献 · Chest · 2023-05-19

BreathCloud 是多中心前瞻性随访研究,用电子鼻(eNose)采集682例慢阻肺患者和211例肺癌患者的呼气谱,随访2年。主成分1、2、3在训练集和验证集区分慢阻肺与肺癌的AUC分别为0.89(95%CI 0.83-0.95)和0.86(95%CI 0.81-0.89)。同样三个主成分在基线区分后续是否发生肺癌的慢阻肺患者,交叉验证值87%,AUC为0.90(95%CI 0.84-0.95)。

要点

  • eNose区分慢阻肺与肺癌的AUC为0.89和0.86。
  • 基线呼气谱可预测2年内肺癌,AUC 0.90。

核心结论

  • 电子鼻呼气分析可识别2年内临床诊断肺癌的慢阻肺患者,可能检测慢阻肺患者早期肺癌。

研究设计与样本

  • BreathCloud为真实世界多中心前瞻性随访研究,在常规诊疗中收集标准化诊断的哮喘、慢阻肺或肺癌患者。
  • 入组时用金属氧化物半导体电子鼻(SpiroNose;Breathomix)置于流量计后端采集呼气谱,每个样本重复采集。
  • 慢阻肺患者按标准临床诊疗管理,前瞻性监测2年内临床诊断肺癌的发生。
  • 数据分析采用先进信号处理、环境空气校正、主成分分析、线性判别分析和受试者工作特征分析。
  • 呼气数据来自682例慢阻肺患者和211例肺癌患者。

主要发现

  • 主成分1、2、3在训练集和验证集中区分慢阻肺与肺癌均显著不同,AUC分别为0.89(95%CI 0.83-0.95)和0.86(95%CI 0.81-0.89)。
  • 同样三个主成分在基线区分2年内是否发生肺癌的慢阻肺患者有显著差异(P < .01),交叉验证值87%,AUC为0.90(95%CI 0.84-0.95)。

临床怎么用

  • 在慢阻肺常规随访中,可考虑用电子鼻呼气分析辅助识别肺癌高风险患者。
  • 呼气谱主成分变化可能作为进一步影像学或专科评估的触发信号。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with COPD are at high risk of lung cancer developing, but no validated predictive biomarkers have been reported to identify these patients. Molecular profiling of exhaled breath by electronic nose (eNose) technology may qualify for early detection of lung cancer in patients with COPD. RESEARCH QUESTION: Can eNose technology be used for prospective detection of early lung cancer in patients with COPD? STUDY DESIGN AND METHODS: BreathCloud is a real-world multicenter prospective follow-up study using diagnostic and monitoring visits in day-to-day clinical care of patients with a standardized diagnosis of asthma, COPD, or lung cancer. Breath profiles were collected at inclusion in duplicate by a metal-oxide semiconductor eNose positioned at the rear end of a pneumotachograph (SpiroNose; Breathomix). All patients with COPD were managed according to standard clinical care, and the incidence of clinically diagnosed lung cancer was prospectively monitored for 2 years. Data analysis involved advanced signal processing, ambient air correction, and statistics based on principal component (PC) analysis, linear discriminant analysis, and receiver operating characteristic analysis. RESULTS: Exhaled breath data from 682 patients with COPD and 211 patients with lung cancer were available. Thirty-seven patients with COPD (5.4%) demonstrated clinically manifest lung cancer within 2 years after inclusion. Principal components 1, 2, and 3 were significantly different between patients with COPD and those with lung cancer in both training and validation sets with areas under the receiver operating characteristic curve of 0.89 (95% CI, 0.83-0.95) and 0.86 (95% CI, 0.81-0.89). The same three PCs showed significant differences (P < .01) at baseline between patients with COPD who did and did not subsequently demonstrate lung cancer within 2 years, with a cross-validation value of 87% and an area under the receiver operating characteristic curve of 0.90 (95% CI, 0.84-0.95). INTERPRETATION: Exhaled breath analysis by eNose identified patients with COPD in whom lung cancer became clinically manifest within 2 years after inclusion. These results show that eNose assessment may detect early stages of lung cancer in patients with COPD.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. de Vries R, Farzan N, Fabius T, et al. Prospective Detection of Early Lung Cancer in Patients With COPD in Regular Care by Electronic Nose Analysis of Exhaled Breath. Chest. 2023. PMID: 37209772. doi:10.1016/j.chest.2023.04.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。